Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. The abstract data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Nivolumab

Nivolumab + Ipilimumab

Notes on CheckMate 214

What About Patients With Favorable Risk?

irAEs

Stopping Checkpoint Inhibition

Combining Targeted and Immunotherapy

IMmotion151

Ongoing Trials Using Combination Therapy

Monotherapy in the First Line

Look to the Future

Concluding Remarks

Abbreviations

Abbreviations (cont)